Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGF-antisense oligonucleotide + pemetrexed + cisplatin
- Development stage
- Unknown
- Lead developer
- University of Alabama at Birmingham
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of a VEGF-antisense oligonucleotide, pemetrexed, and cisplatin. The VEGF-antisense oligonucleotide is designed to inhibit the expression of vascular endothelial growth factor A (VEGFA), thereby reducing angiogenesis in tumors by blocking transcription or translation and promoting mRNA degradation via RNase H cleavage. Pemetrexed is an antifolate chemotherapeutic agent that inhibits folate-dependent enzymes involved in nucleotide synthesis, leading to impaired DNA and RNA synthesis and subsequent cell death. Cisplatin is a platinum-based chemotherapy drug that forms DNA crosslinks, resulting in apoptosis of rapidly dividing cells. This combination has been investigated for the treatment of advanced malignant mesothelioma[2][3][8].
- Brand names
- Alimta
- Other names
- VEGF-antisense oligonucleotide + pemetrexed + cisplatin
02
Targets
VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)
Beyond the preview
Go deeper on VEGF-antisense oligonucleotide + pemetrexed + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGF-antisense oligonucleotide + pemetrexed + cisplatin.